Alcanza Clinical Research acquires FDI Clinical Research to enhance patient representation in clinical trials

Alcanza Clinical Research, a prominent investigator site network focused on inclusive clinical trials, has announced its acquisition of FDI Clinical Research, a comprehensive multi-specialty research organization based in San Juan, Puerto Rico. FDI Clinical Research, which also operates an additional site in Mayagüez, specializes in a wide range of therapeutic areas and is known for its extensive experience in Phase I-IV clinical trials.

FDI Clinical Research, established in 2002, brings a wealth of expertise, particularly in endocrine and metabolic conditions, immunology, hepatology, infectious diseases, oncology, respiratory diseases, and rheumatology. The organization’s headquarters in San Juan features a dedicated Phase I unit capable of conducting complex studies, including first-in-human clinical pharmacology trials. This acquisition significantly enhances Alcanza’s research capabilities and its ability to offer trials to a more diverse patient demographic.

Carlos Orantes, CEO of Alcanza Clinical Research, emphasized the strategic value of the acquisition, stating, “The addition of FDI to the Alcanza site network accelerates our ability to reach more patients who are not traditionally represented with research participation opportunities across a range of increasingly prevalent diseases.” Orantes highlighted FDI’s robust therapeutic expertise and its commitment to reducing barriers to participation through patient-friendly services.

Dr. José F. Rodríguez-Orengo, CEO of FDI, expressed enthusiasm about joining forces with Alcanza. “Joining Alcanza will allow us to further our mission of providing equitable access for all Puerto Ricans to promising new medicines,” he noted. Dr. Rodríguez-Orengo also pointed out the potential for community-focused research to expand and integrate more closely with clinical care, enhancing patient access to new treatments.

Alcanza Clinical Research operates an extensive network of 22 dedicated research units and additional sites integrated within specialty clinics across the Southeast, Northeast, and Midwest regions of the United States. The network is dedicated to enhancing access to clinical trials, especially for underrepresented populations, across all major therapeutic areas and trial phases.

FDI Clinical Research is renowned for its state-of-the-art facilities and expertise in managing clinical trials from Phase I to IV, supporting both biopharmaceutical sponsors and contract research organizations. The organization has a strong focus on a variety of therapeutic areas, including infectious diseases like hepatitis and influenza, as well as chronic conditions such as diabetes and rheumatoid arthritis.